WHO Landscape COVID Vaccine - 29 January 2021

Landscape COVID Vaccine

29 January 2021
• 63 candidate vaccines in clinical evaluation
• Phase three – candidate vaccines
• University of Oxford/AstraZeneca - Non-Replicating Viral Vector
• CanSino - Non-Replicating Viral Vector
• Gamaleya - Non-Replicating Viral Vector
• Jansen - Non-Replicating Viral Vector
• Sinovac – Inactivated
• Wuhan Institute of Biological Products/Sinopharm - Inactivated
• Beijing Institute of Biological Products/Sinopharm - Inactivated
• Moderna/NIAID – RNA
• Novavax - Protein Subunit
• Bharat Biotech – Inactivated
• Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology - Protein Subunit
• BioNTech/Fosun Pharma/Pfizer – RNA

• 174 candidate vaccines in preclinical evaluation

 Antisipasi
1. Efikasi (90an%, atau kurang, lebih dari 50%)
2. Cara pemberian
3. Berapa lama proteksi bertahan (orang sembuh - bbrp
bulan)
4. Untuk semua umur, anak-anak, ko-morbid, dll.
5. Distribusi (cold chain, daerah terpencil)
6. Mutasi virus
7. Kelompok menolak di vaksin
8. Post Marketing Surveillance
Risiko sakit- plasebo
162/21681 = 0.74%

Risiko sakit vaksin 8/21669

= 0.036%

RR: 0.036%/0.74% = 4.9%,

dibulatkan 5%

Jadi efikasi : 100%-5%

= 95%
Cara Pemberian
Johnson & Johnson
COVID-19 Vaccine Acceptance Survey
in Indonesia .
 COVID-19 vaccine acceptance status
If Government of Indonesia offers you COVID 19 vaccine, will you take it for yourself and
your family members?

(n=112.888)
 Strategic Advisory Group of Experts (SAGE) on
Immunization
https://www.who.int/docs/default-source/immunization/sage/covid/sage-prioritization-roadmap-covid19-vaccines.pdf?Status=Temp&sfvrsn=bf227443_2&ua=1
38
Light at the end of the tunnel
• Agent – mutasi

• Host – restriction fatigue – protokol

kesehatan (3M + “M lainnya”)

•Penemuan alat Diagnosis, Obat dan

Vaksin
•Perkembangan epidemiologi pandemi

•Monitor dan Evaluasi

TERIMAKASIH